# Boston Scientific Corp: overview

BSX · NYSE · CIK 885725 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bsx.md) · [Financials](/companies/bsx/financials.md) · [Filings](/companies/bsx/filings.md) · [Insiders](/companies/bsx/insiders.md)

Latest reported revenue: [$5.44bn](/filings/0000885725-26-000053.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 3, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0000885725-26-000053).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [4,209](/filings/0000885725-25-000050.md) | [4,561 d](/filings/0000885725-26-000010.md) | [4,663](/filings/0000885725-26-000033.md) | [5,061](/filings/0000885725-26-000053.md) | [5,065](/filings/0000885725-25-000050.md) | [5,286 d](/filings/0000885725-26-000010.md) | [5,203](/filings/0000885725-26-000033.md) | [5,442](/filings/0000885725-26-000053.md) |
| Gross margin | % | [68.8%](/filings/0000885725-25-000050.md) | [67.9% d](/filings/0000885725-26-000010.md) | [68.8%](/filings/0000885725-26-000033.md) | [67.7%](/filings/0000885725-26-000053.md) | [69.9%](/filings/0000885725-25-000050.md) | [69.6% d](/filings/0000885725-26-000010.md) | [69.5%](/filings/0000885725-26-000033.md) | [70.7%](/filings/0000885725-26-000053.md) |
| Operating margin | % | [17.4%](/filings/0000885725-25-000050.md) | [14.8% d](/filings/0000885725-26-000010.md) | [19.8%](/filings/0000885725-26-000033.md) | [16.2%](/filings/0000885725-26-000053.md) | [20.7%](/filings/0000885725-25-000050.md) | [15.6% d](/filings/0000885725-26-000010.md) | [21.2%](/filings/0000885725-26-000033.md) | [21.6%](/filings/0000885725-26-000053.md) |
| Net margin | % | [11.1%](/filings/0000885725-25-000050.md) | [12.3% d](/filings/0000885725-26-000010.md) | [14.4%](/filings/0000885725-26-000033.md) | [15.7%](/filings/0000885725-26-000053.md) | [14.9%](/filings/0000885725-25-000050.md) | [12.7% d](/filings/0000885725-26-000010.md) | [25.7%](/filings/0000885725-26-000033.md) | [16.6%](/filings/0000885725-26-000053.md) |
| Diluted EPS | $ per share | [0.32](/filings/0000885725-25-000050.md) | not reported | [0.45](/filings/0000885725-26-000033.md) | [0.53](/filings/0000885725-26-000053.md) | [0.51](/filings/0000885725-25-000050.md) | not reported | [0.90](/filings/0000885725-26-000033.md) | [0.61](/filings/0000885725-26-000053.md) |
| Free cash flow | $m | [823 d](/filings/0000885725-25-000050.md) | [1,179 d](/filings/0000885725-26-000010.md) | [354](/filings/0000885725-26-000033.md) | [1,129 d](/filings/0000885725-26-000053.md) | [1,162 d](/filings/0000885725-25-000050.md) | [1,013 d](/filings/0000885725-26-000010.md) | [171](/filings/0000885725-26-000033.md) | [1,279 d](/filings/0000885725-26-000053.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [11.9](/filings/0000885725-24-000017.md) | [12.7](/filings/0000885725-25-000011.md) | [14.2](/filings/0000885725-26-000010.md) | [16.7](/filings/0000885725-26-000010.md) | [20.1](/filings/0000885725-26-000010.md) |
| Gross margin | % | [68.8%](/filings/0000885725-24-000017.md) | [68.8%](/filings/0000885725-25-000011.md) | [69.5%](/filings/0000885725-26-000010.md) | [68.6%](/filings/0000885725-26-000010.md) | [69.0%](/filings/0000885725-26-000010.md) |
| Operating margin | % | [10.1%](/filings/0000885725-24-000017.md) | [13.0%](/filings/0000885725-25-000011.md) | [16.5%](/filings/0000885725-26-000010.md) | [15.5%](/filings/0000885725-26-000010.md) | [18.0%](/filings/0000885725-26-000010.md) |
| Net margin | % | [8.8%](/filings/0000885725-24-000017.md) | [5.5%](/filings/0000885725-25-000011.md) | [11.2%](/filings/0000885725-26-000010.md) | [11.0%](/filings/0000885725-26-000010.md) | [14.4%](/filings/0000885725-26-000010.md) |
| Diluted EPS | $ per share | [0.69](/filings/0000885725-24-000017.md) | [0.45](/filings/0000885725-25-000011.md) | [1.07](/filings/0000885725-26-000010.md) | [1.25](/filings/0000885725-26-000010.md) | [1.94](/filings/0000885725-26-000010.md) |
| Free cash flow | $bn | [1.3](/filings/0000885725-24-000017.md) | [0.9](/filings/0000885725-25-000011.md) | [1.8](/filings/0000885725-26-000010.md) | [2.6](/filings/0000885725-26-000010.md) | [3.7](/filings/0000885725-26-000010.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bsx/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $5.53bn | 129,680,916 |  | Reduced −2,141,121 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $4.14bn | 97,087,553 |  | Added +675,985 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $2.99bn | 70,111,196 |  | Added +2,124,349 |
| [PRIMECAP MANAGEMENT CO/CA/](/funds/763212.md) | 2026-06-30 | $2.16bn | 50,520,914 |  | Added +17,991,140 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $1.95bn | 45,702,845 |  | Reduced −28,523,550 |
| [MASSACHUSETTS FINANCIAL SERVICES CO /MA/](/funds/912938.md) | 2026-06-30 | $1.50bn | 24,859,191 |  | Added +13,862,619 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $1.42bn | 33,440,102 |  | Added +154,345 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $1.27bn | 29,792,794 |  | Reduced −3,417 |
| [D. E. Shaw & Co., Inc.](/funds/1009207.md) | 2026-06-30 | $1.09bn | 25,457,409 |  | Added +1,145,057 |
| [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $1.04bn | 23,907,838 |  | Reduced −9,442,319 |

## Recent filings

[All 3,572 filings](/companies/bsx/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-07 | 06:11 ET | [8-K](/filings/0000885725-26-000064.md) | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0000885725-26-000064 |
| 2026-09-23 | 06:01 ET | [8-K](/filings/0000885725-26-000061.md) | 5.02 Departure or appointment of officers or directors | 0000885725-26-000061 |
| 2026-09-08 | 06:15 ET | [8-K](/filings/0000885725-26-000059.md) | 1.05 Material cybersecurity incident | 0000885725-26-000059 |
| 2026-08-26 | 06:06 ET | [8-K](/filings/0000885725-26-000056.md) | 8.01 Other events | 0000885725-26-000056 |
| 2026-08-03 | 06:32 ET | [10-Q](/filings/0000885725-26-000053.md) | Quarterly report, period 2026-06-30 | 0000885725-26-000053 |
| 2026-07-29 | 06:33 ET | [8-K](/filings/0000885725-26-000051.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000885725-26-000051 |
| 2026-07-27 | 16:06 ET | [8-K](/filings/0000885725-26-000049.md) | 2.05 Exit or disposal costs | 0000885725-26-000049 |
| 2026-05-18 | 07:17 ET | [8-K](/filings/0000885725-26-000042.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0000885725-26-000042 |
| 2026-05-18 | 07:15 ET | [8-K](/filings/0000885725-26-000041.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0000885725-26-000041 |
| 2026-05-05 | 16:47 ET | [8-K](/filings/0000885725-26-000036.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000885725-26-000036 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0000885725-26-000010.md), filed Feb 17, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/ae07b64a-7856-4307-8dca-d0dbfdde9abd)

## About the filer

- CIK: 885725
- Tickers: BSX
- Exchange: NYSE
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 28, 2026, 06:35 ET. No prices; not investment advice.